Andrew Dickinson appointed as non-executive non-independent director of Galapagos
28-03-2024 Andrew Dickinson has been appointed as a non-executive director at Galapagos as of March 26. He replaces Daniel O'Day.
In 2016 Andrew Dickinson joined Gilead, that has a longstanding partnership with Galapagos. Currently he is Gilead’s Chief Financial Officer. Prior to his current role as CFO, he served as head of the company’s corporate development and strategy group. Before joining Gilead, Dickinson worked at Lazard as global co-head of the healthcare investment banking division. Earlier in his career, he served as general counsel and vice president of corporate development at Myogen, Inc., which was acquired by Gilead in 2006. Dickinson is also a member of the Board of Directors of Sutter Health.
Dickinson replaces Daniel O’Day, Gilead’s Chairman and Chief Executive Officer (CEO), who was a member of the Galapagos Board of Directors from 22 October 2019 to 26 March 2024.
“On behalf of the Galapagos Board of Directors, Dr. Paul Stoffels, CEO and Chairman of Galapagos expresses great pleasure in welcoming Dickinson to the board: “Dickinson brings valuable experience in corporate development, financial transactions and investment decision making to our Board as we continue to position our company for value creation for all our stakeholders.”